Overview

* Maravai Q3 revenue falls 39.7% yr/yr, missing analyst expectations

* Adjusted EBITDA for Q3 misses analyst estimates, reflecting operational challenges

* Biologics Safety Testing revenue grows 7.2% yr/yr, driven by strong product lines

Outlook

* Maravai expects full-year 2025 revenue to be approximately $185 mln

* Company anticipates TriLink to achieve double-digit sequential revenue growth in Q4 2025

* Maravai aims for attractive financial results in Q4 2025 and 2026

Result Drivers

* NUCLEIC ACID PRODUCTION - Revenue decreased 52.9% due to lack of high-volume CleanCap orders and non-recurring large GMP orders

* BIOLOGICS SAFETY TESTING - Revenue increased 7.2% due to strength in nearly all product lines

* RESTRUCTURING AND COST REDUCTION - Organizational restructuring and cost reduction initiatives are on track, expected to improve future financial results

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $41.60 $49.003

Revenue mln mln (11

Analysts

)

Q3 Net -$45.10

Income mln

Q3 Miss -$10.80 -$7.41

Adjusted mln mln (10

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Maravai LifeSciences Holdings Inc ( MRVI ) is $4.50, about 36.2% above its November 5 closing price of $2.87

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)